OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	544
Towards reparatory measures: blood donation, health systems, and men who have sex with men	439
In the trenches	233
Prioritising health equity alongside donation safety – Authors' reply	214
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	206
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	192
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	143
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	141
Correction to Lancet Haematol 2023; 10: e333–45	138
Correction to Lancet Haematol 2024; 11: e114–26	136
MRD-guided treatment cessation in multiple myeloma	135
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	125
Zanubrutinib-associated ecchymotic lesions	114
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	104
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	102
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	97
Blood cell defence against pathogens	91
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	89
Blood deserts: a vision to tackle blood inaccessibility	84
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	83
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	82
Extensively distributed erythema nodosum in VEXAS syndrome	81
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	81
International Society on Thrombosis and Haemostasis Congress 2023	80
Bedside art is good medicine	80

Be compliant or compromise?	77
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	77
Production and supply of blood products in Brazil	76
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	76
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	76
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	75
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	72
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	72
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	69
USAID's enduring impact on anaemia management must be preserved	68
Anaemia in a time of climate crisis	65
Correction to Lancet Haematol 2023; 10: e433–44	64
Coexisting genetic abnormalities and thrombocytopenia	64
Correction to Lancet Haematol 2025; 12: e294–303	63
Rituximab versus active surveillance in patients with follicular lymphoma	62
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	61
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	60
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	56
Sickle cell disease in India: current status and progress	56
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	55
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	55
Oreofe Odejide—aiming to raise the bar in haematology care	54
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	53
Universal health coverage for children with cancer	53
Could improving mental health disorders help increase cancer survival?	52
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	52
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	51
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	51
Correction to Lancet Haematol 2022; 9: e200–07	47
Correction to Lancet Haematol 2024; 11: e310–11	46
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	46
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	46
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	45
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass	45
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	44
Striking the right balance	43
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	43
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	43
Patients first: improving toxicity assessment and reporting	42
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	42
2024 ASH Annual Meeting	42
Haematology and climate change	42
Haemophilia—unparalleled progress but inadequate access	41
A long-awaited benchmark in lymphomatoid granulomatosis	40
Secondary haematological malignancies	39
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	38
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	37
Should patients with haemophilia receive gene therapy?	36
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	36
Correction to Lancet Haematol 2024; 11: e521–29	35

Thank you to our 2022 peer reviewers and an update on inclusion and diversity	35
Acute myeloid leukaemia at the extremes	35
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors' reply	34
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	34
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial	34
Updated anaemia estimates: implications for global monitoring	33
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	33
Sickle cell disease—unity and patient-centred education	33
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	33
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	32
The challenge of defining the global burden of iron deficiency anaemia	32
Leprosy and leukaemia: an unexpected interaction	31
The Lancet Haematology at 10	31
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	30
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	30
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	28
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial	28
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	28
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	28
Life beyond blood disorders	27
Breaking sex biases: access for all in haemophilia care	27
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	27
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	27
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	27
Thank you to The Lancet Haematology's peer reviewers in 2022	27
Sovleplenib in immune thrombocytopenia	27
Gene therapy in China: past, present, and future	27
Don Thomas: leading the charge to bone marrow transplantation	26
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	26
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	26
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	26
Making a case for disease-modifying agents in myelofibrosis	26
A treatise on clinical trials	26
Needles were the least of my worries	26
Acquired haemophilia in an Edo period Japanese surgical casebook	26
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	26
Monumen-TAL progress in the treatment of relapsed multiple myeloma	25
Experience of the Anaemia Mukt Bharat anaemia control programme in India	25
Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial	25
Virtual twins for personalised CAR T-cell therapy in myeloma	24
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	24
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM	24
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	23
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	23
Clinical trial design change implementation for inclusive studies	23
From diagnosis to equitable care in bleeding disorders	23
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	22
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	21
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	20
Epistemic limitations of measurable residual disease in haematological malignancies	20
Antifibrinolytics do not add to the benefits of platelet transfusion	20
Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England	20
Correction to Lancet Haematol 2025; 12: e562–63	20
Lines of the haematology community	20
The effects of revised haemoglobin cutoffs on the global burden of anaemia	20
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	20
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	19
Mitapivat for treatment of pyruvate kinase deficiency	19
Making blood count	19
Reducing toxic waste: improving toxicity capture in childhood cancer	19
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	19
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	19
Sickle cell disease: a neglected health priority	18
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial	18
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	18
2025 ASH Annual Meeting	18
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	17
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	17
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	17
Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study	17
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	17
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	17
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	17
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	17
Sexually transmitted infections in the context of haematological malignancies	16
Correction to Lancet Haematol 2023; 10: e203–12	16
An integrated approach to cardioprotection in lymphomas	16
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	16
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	16
Correction to Lancet Haematol 2024; 11: e862–72	16

Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	15
New hope, old challenges in myelodysplastic syndromes	15
Lallindra Gooneratne—maintaining treatment flow amid crisis	15
Iron deficiency anaemia—an ongoing challenge	15
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	15
Reactivating hope for TP53-mutated acute myeloid leukaemia?	14
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	14
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	14
Time to define and refine maintenance strategies in acute myeloid leukaemia	14
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	14
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	14
Long term strategies for individuals with sickle cell disease	14
Oncology service priorities for the new UK Government	14
Concerns on perioperative anaemia management in the FIT trial	13
Virginia Abello Polo—a once-in-a-lifetime opportunity	13
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	13
Isolated IgG4-related disease of the left maxillary antrum	13
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	13
Correction to Lancet Haematol 2025; 12: e808–22	12
Correction to Lancet Haematol 2023; 10: e713–34	12
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	12
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial	12
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	12
Fitusiran prophylaxis in severe haemophilia without inhibitors	12
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	12
Mental health and psychological resilience in sickle cell disease	12
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	12
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	12
Correction to Lancet Haematol 2025; 12: e128–37	12
CAR T-cell therapies in China: rapid evolution and a bright future	11
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	11
Environmental impact of haematology care—measurement and mitigation	11
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial	11
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	11
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib	11
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	11
Cristóbal Frutos: confronting treatment barriers	11
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	11
Correction to Lancet Haematol 2024; 11: e38–50	10
CAR T-cell therapy: navigating real-world challenges beyond clinical trials	10
Ending the burden of sickle cell disease in Africa	9
Adverse event grading: the case of Duffy null-associated neutrophil counts	9
Maintaining MOMENTUM in myelofibrosis	9
48th Annual Meeting of the EBMT	9
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia	9
Correction to Lancet Haematol 2024; 11: e510–20	9
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	9
A curious case of a neutrophilic horn	9